EA032263B1 - Применение ингибиторов ccr3 - Google Patents
Применение ингибиторов ccr3 Download PDFInfo
- Publication number
- EA032263B1 EA032263B1 EA201401083A EA201401083A EA032263B1 EA 032263 B1 EA032263 B1 EA 032263B1 EA 201401083 A EA201401083 A EA 201401083A EA 201401083 A EA201401083 A EA 201401083A EA 032263 B1 EA032263 B1 EA 032263B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- chloride
- treatment
- eosinophilic
- alkyl
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937.2 | 2012-04-03 | ||
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201401083A1 EA201401083A1 (ru) | 2015-03-31 |
| EA032263B1 true EA032263B1 (ru) | 2019-05-31 |
Family
ID=48040249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201401083A EA032263B1 (ru) | 2012-04-03 | 2013-04-02 | Применение ингибиторов ccr3 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (https=) |
| EP (3) | EP4389217A3 (https=) |
| JP (2) | JP2015512432A (https=) |
| KR (5) | KR20140144200A (https=) |
| CN (2) | CN104220073A (https=) |
| AU (1) | AU2013245027B2 (https=) |
| BR (1) | BR112014023795B1 (https=) |
| CA (1) | CA2869269C (https=) |
| CL (1) | CL2014002523A1 (https=) |
| CY (1) | CY1123222T1 (https=) |
| DK (1) | DK2833884T3 (https=) |
| EA (1) | EA032263B1 (https=) |
| ES (2) | ES2811554T3 (https=) |
| HR (1) | HRP20201165T1 (https=) |
| HU (1) | HUE051648T2 (https=) |
| IL (1) | IL234262A (https=) |
| IN (1) | IN2014DN06989A (https=) |
| LT (1) | LT2833884T (https=) |
| MX (1) | MX2014011786A (https=) |
| NZ (1) | NZ628882A (https=) |
| PH (1) | PH12014502239A1 (https=) |
| PL (1) | PL2833884T3 (https=) |
| PT (1) | PT2833884T (https=) |
| RS (1) | RS60665B1 (https=) |
| SI (1) | SI2833884T1 (https=) |
| SM (1) | SMT202000499T1 (https=) |
| WO (1) | WO2013149986A1 (https=) |
| ZA (1) | ZA201406082B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| JP6684363B2 (ja) | 2016-11-24 | 2020-04-22 | キリシマ精工株式会社 | 歯列矯正具 |
| MY199462A (en) * | 2017-04-05 | 2023-10-30 | Alkahest Inc | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
| SG11201909245PA (en) | 2017-04-05 | 2019-11-28 | Alkahest Inc | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| CA3076017A1 (en) * | 2017-10-13 | 2019-04-18 | Alkahest, Inc. | Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors |
| MY198220A (en) | 2018-05-15 | 2023-08-14 | Alkahest Inc | Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase |
| CN112789044A (zh) * | 2018-09-26 | 2021-05-11 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| AU2021287906B2 (en) | 2020-06-11 | 2025-09-11 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
| AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US20090123375A1 (en) * | 2007-10-09 | 2009-05-14 | University Of Kentucky Research Foundation | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration |
| WO2010115836A1 (en) * | 2009-04-08 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Substituted piperidines as ccr3 antagonists |
| WO2012045803A1 (en) * | 2010-10-07 | 2012-04-12 | Boehringer Ingelheim International Gmbh | Co-crystals and salts of ccr3-inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| BRPI0108923B8 (pt) * | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| WO2010138591A1 (en) * | 2009-05-26 | 2010-12-02 | University Of Kentucky Research Foundation | Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006083390A2 (en) * | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| US20090123375A1 (en) * | 2007-10-09 | 2009-05-14 | University Of Kentucky Research Foundation | CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration |
| WO2010115836A1 (en) * | 2009-04-08 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Substituted piperidines as ccr3 antagonists |
| WO2012045803A1 (en) * | 2010-10-07 | 2012-04-12 | Boehringer Ingelheim International Gmbh | Co-crystals and salts of ccr3-inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| ATSUNOBU TAKEDA, JUDIT Z. BAFFI, MARK E. KLEINMAN, WON GIL CHO, MIHO NOZAKI, KIYOSHI YAMADA, HIROKI KANEKO, ROMULO J. C. ALBUQUERQ: "CCR3 is a target for age-related macular degeneration diagnosis and therapy", NATURE, MACMILLAN JOURNALS LTD., LONDON, vol. 460, no. 7252, 9 July 2009 (2009-07-09), London, pages 225 - 30, XP002693828, ISSN: 0028-0836, DOI: 10.1038/NATURE08151 * |
| BACHERT C, WATELET J B, GEVAERT P, VAN CAUWENBERGE P.: "Pharmacological management of nasal polyposis", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 65, no. 11, 1 January 2005 (2005-01-01), NZ, pages 1537 - 1552, XP002697885, ISSN: 0012-6667, DOI: 10.2165/00003495-200565110-00006 * |
| BLANCHARD C, ET AL.: "Eotaxin-3 and a Uniquely Conserved Gene-Expression profile in Eosinophilic Esophagitis", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 116, no. 2, 1 February 2006 (2006-02-01), GB, pages 536 - 547, XP003003549, ISSN: 0021-9738, DOI: 10.1172/JCI26679 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA032263B1 (ru) | Применение ингибиторов ccr3 | |
| JP6118273B2 (ja) | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 | |
| JP2011503045A (ja) | Ｃｒｔｈ２拮抗化合物の使用 | |
| HUP0204079A2 (hu) | Szedatív hatástól mentes antihisztaminok és leukotrién hatást befolyásoló anyagok új kombinációja orrnyálkahártya-gyulladás, vagy kötőhártya-gyulladás kezelésére | |
| EA020987B1 (ru) | Ассоциация между 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1h)-ил]пропокси}бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат | |
| EA021461B1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ | |
| RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
| WO2012133489A1 (ja) | 神経性疾患の治療又は予防のための医薬組成物 | |
| WO2020221894A1 (en) | Antiviral compounds | |
| JP5366807B2 (ja) | Ｔ細胞のＴｈ１細胞への分化抑制剤 | |
| HK40015701A (en) | Use of ccr3-inhibitors | |
| JP5978472B2 (ja) | 耳鳴患者の治療用の薬剤 | |
| CN104981243A (zh) | 含有四氢吡喃基氨基环戊基羰基四氢吡啶并吡啶衍生物作为有效成分的眼后段疾病的预防或治疗剂 | |
| US20090203701A1 (en) | Prophylactic and/or therapeutic agent for rheumatoid arthritis | |
| WO2001058488A1 (en) | Remedies for sjoegren's syndrome | |
| JPWO2007049732A1 (ja) | 関節リウマチの予防及び／又は治療法 | |
| JPWO2017126648A1 (ja) | Ｎ−［７−［（メチルスルホニル）アミノ］−４−オキソ−６−フェノキシ−４ｈ−１−ベンゾピラン−３−イル］ホルムアミドまたはその塩を含有する医薬組成物 |